Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.80 |
| ▸ | PGR | P06401 | 5/20 | 0.80 |
| ▸ | LMNA | P02545 | 4/20 | 0.80 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.80 |
| ▸ | AR | P10275 | 3/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.80 |
| ▸ | USP2 | O75604 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.58 |
| ▸ | MLNR | O43193 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18787576 | 1.00 | CYP3A4 (0.80) | CYP3A4PGRLMNANR3C1ADORA3 | |
| SCHEMBL4569 | 0.94 | CYP3A4 (0.84) | CYP3A4PGRLMNANR3C1ADORA3 | |
| Propionic Acid SCHEMBL18787577 | 0.94 | CYP3A4 (0.79) | CYP3A4PGRLMNANR3C1ADORA3 | |
| Water SCHEMBL142488 | 0.94 | CYP3A4 (0.83) | CYP3A4PGRLMNANR3C1ADORA3 | |
| SCHEMBL6667323 | 0.93 | CYP3A4 (0.82) | CYP3A4PGRLMNANR3C1ADORA3 | |
| Furan SCHEMBL5473562 | 0.91 | CYP3A4 (0.78) | CYP3A4PGRLMNANR3C1ADORA3 | |
| SCHEMBL4444301 | 0.90 | CYP3A4 (0.76) | CYP3A4PGRLMNANR3C1ADORA3 | |
| Mometasone Furoate SCHEMBL25382496 | 0.89 | CYP3A4 (1.00) | CYP3A4PGRLMNANR3C1ADORA3 | |
| Mometasone Furoate SCHEMBL2594997 | 0.89 | CYP3A4 (1.00) | CYP3A4PGRLMNANR3C1ADORA3 | |
| Mometasone Furoate SCHEMBL8826257 | 0.89 | CYP3A4 (1.00) | CYP3A4PGRLMNANR3C1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112933064-A | Salmeterol xinafoate particle for inhalation and preparation method thereof | 深圳市海滨制药有限公司 | 2021-06-11 | — | — | CN | claimed |
| EP-1455873-A1 | METERED DOSE INHALER | CHIESI FARMACEUTICI S.p.A. (IT) | 2004-09-15 | — | — | EP | claimed |
| US-20030178022-A1 | Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators | CHIESI FARMACEUTICI S.P.A. | 2003-09-25 | — | — | US | claimed |
| WO-2003053501-A1 | METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2003-07-03 | — | — | WO | claimed |
| EP-1321159-A1 | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices | CHIESI FARMACEUTICI S.p.A. (IT) | 2003-06-25 | — | — | EP | claimed |
| US-20230181555-A1 | STABLE AND PRESERVED PHARMACEUTICAL COMPOSITIONS OF BILASTINE | FAES FARMA, S.A. (ES) | 2023-06-15 | — | — | US | disclosed |
| US-11642309-B2 | Aqueous compositions comprising bilastine and mometasone | FAES FARMA, S.A. (ES) | 2023-05-09 | — | — | US | disclosed |
| CN-114390928-A | Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept | 阿德夫拉姆生物技术股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114375195-A | Methods of treating ocular neovascular diseases using AAV2 variants encoding aflibercept | 阿德夫拉姆生物技术股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114007588-A | Stable and preserved pharmaceutical composition of bilastine | 费斯制药股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210186869-A1 | AQUEOUS COMPOSITIONS COMPRISING BILASTINE AND MOMETASONE | FAES FARMA, S.A. (ES) | 2021-06-24 | — | — | US | disclosed |
| CN-112933064-A | Salmeterol xinafoate particle for inhalation and preparation method thereof | 深圳市海滨制药有限公司 | 2021-06-11 | — | — | CN | disclosed |
| WO-2019076798-A1 | AQUEOUS COMPOSITIONS COMPRISING BILASTINE AND MOMETASONE | FAES FARMA, S.A. (ES) | 2019-04-25 | — | — | WO | disclosed |
| WO-2017091167-A1 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING FUSIDIC ACID, ISOCONAZOLE, DEXPANTHENOL AND HYDROCORTISONE | PHARMACTİVE İLAÇ SAN. VE TİC. A.Ş. (TR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2012023082-A1 | A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, A CORTICOSTEROID - HYDROCORTISONE ACETATE, AND AN ANTIFUNGAL AGENT - TERBINAFINE HYDROCHLORIDE, AND A PROCESS TO MAKE IT | VANANGAMUDI SULUR SUBRAMANIAM (IN) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012017370-A1 | A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER, BETAMETHASONE DIPROPIONATE, TERBINAFINE HYDROCHLORIDE AND A PROCESS TO MAKE IT | VANANGAMUDI SULUR SUBRAMANIAM (IN) | 2012-02-09 | — | — | WO | disclosed |
| EP-1455873-A1 | METERED DOSE INHALER | CHIESI FARMACEUTICI S.p.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-20030178022-A1 | Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators | CHIESI FARMACEUTICI S.P.A. | 2003-09-25 | — | — | US | disclosed |
| WO-2003053501-A1 | METERED DOSE INHALER | CHIESI FARMACEUTICI S.P.A. (IT) | 2003-07-03 | — | — | WO | disclosed |
| EP-1321159-A1 | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices | CHIESI FARMACEUTICI S.p.A. (IT) | 2003-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186869-A1 | AQUEOUS COMPOSITIONS COMPRISING BILASTINE AND MOMETASONE | HRH4, HRH2, HRH1 | CYP3A4 196/4885PGR 752/4885LMNA 4077/4885 |
| US-20230181555-A1 | STABLE AND PRESERVED PHARMACEUTICAL COMPOSITIONS OF BILASTINE | HRH4, CNR2, CNR1 | CYP3A4 249/4885PGR 2182/4885LMNA 2539/4885 |
| US-11642309-B2 | Aqueous compositions comprising bilastine and mometasone | HRH4, HRH2, HRH1 | CYP3A4 196/4885PGR 752/4885LMNA 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.